Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

@article{Krastins2013RapidDO,
  title={Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.},
  author={Bryan Krastins and Amol Prakash and David A. Sarracino and Dobrin Nedelkov and Eric E. Niederkofler and Urban A. Kiernan and Randall S Nelson and Maryann S Vogelsang and Gouri Vadali and Alejandra Garces and Jennifer N. Sutton and Scott M. Peterman and Gregory Byram and Bruno Darbouret and Jo{\"e}lle R. P{\'e}russe and Nabil G Seidah and Benoit Coulombe and Johan Gobom and Erik Portelius and Josef Pannee and K Blennow and Vathany Kulasingam and Lewis Couchman and C. V. D. Moniz and Mary F. Lopez},
  journal={Clinical biochemistry},
  year={2013},
  volume={46 6},
  pages={
          399-410
        }
}

• Bryan Krastins, Amol Prakash, +22 authors Mary F. Lopez
• Published 2013 in Clinical biochemistry
• DOI:10.1016/j.clinbiochem.2012.12.019

OBJECTIVES The aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma or serum. DESIGN AND METHODS The described method coupled mass spectrometric immunoassay (MSIA), a previously developed technique for immunoenrichment on a monolithic microcolumn activated with an anti-protein antibody and fixed in a pipette tip, to selected reaction monitoring (SRM) detection and… CONTINUE READING

Save to Library

Create Alert

Cite

View on PubMed